Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 10Gastrointestinal 6Thoracic 3Gynecologic 2Dermatologic 2Lymphoid 1Head & Neck 1Genitourinary 1

Conditions

Ovarian Neoplasms 2Peripheral Nervous System Diseases 1Pain 1Breast Neoplasms 1

Interventions

Paclitaxel 581Carboplatin 528Cisplatin 359Bevacizumab 256pembrolizumab 228Gemcitabine 157liposomal doxorubicin 132Topotecan 131olaparib 129Cyclophosphamide 128Radiotherapy 118Taxes 114Docetaxel 95Brachytherapy 94Drug Therapy 91niraparib 88Doxorubicin 86Surveys and Questionnaires 85Magnetic Resonance Spectroscopy 80Blood Specimen Collection 74Nivolumab 71Specimen Handling 70Hyperthermic Intraperitoneal Chemotherapy 64Biopsy 63fludarabine 57Filgrastim 53Letrozole 50Oxaliplatin 49durvalumab 47Immunoglobulin G 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Omacor × Gynecologic × Clear all
NCT03197584 2025-02-21

QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Gynecologic

Ovarian Neoplasms

NCT01821833 2022-10-05

Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel

New Mexico Cancer Research Alliance

Phase NA Completed
60 enrolled
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pain, Peripheral Nervous System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡